"Both semaglutide and tirzepatide are well-known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and type 2 diabetes by reducing adverse heart failure outcomes." Despite promising results from existing randomized controlled trials of semaglutide and tirzepatide in those with obesity-related HFpEF, regulatory authorities and professional societies have not approved or endorsed the use of these drugs for HFpEF, due in part to the studies relatively small sample sizes and unknown generalizability
Background Under our current Extraordinary Circumstances Exception (ECE) regulations, we have granted exceptions to data submission deadlines and requirements for the Hospital OQR, REHQR, and ASCQR Programs in the event of extraordinary circumstances beyond the control of a hospital, REH, or ASC (42 CFR 419.46(e), 419.95(g), 416.310(d), respectively)
[PMC free article] [PubMed] [Google Scholar] 876.Vilsboll T., Agerso H., Krarup T., Holst J.J
Neil Shah of The Wall Street Journal deemed it "a big moment for female rappers" and "a historic sign that women artists are making their mark on hip-hop like never before"
